ClinicalTrials.gg
RecruitingNCT04414956Updated Jun 4, 2020

Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

An interventional study of AFP-L3 and AFP in Liver Cirrhosis, Hepatocellular Carcinoma and Surveillance, sponsored by Korea University. Recruiting at 15 sites in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Korea University · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 4 months ago, but the record still lists the study as recruiting.
  • Registered 3 years 10 months after the study started (first participant enrolled Jul 2016, registered May 2020).
  • Started Jul 2016; still recruiting 10 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,418
Allocation
Not applicable
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Liver Cirrhosis with a site in Korea, Republic of — 8 open to participants now, 11 under way, 2 of them phase 3. Liver Cirrhosis · Korea, Republic of.

Planned enrollment
3rd of 32
1,418 · median 125
Started
2016
with 2 others
No phase
14 of 61
2 open now
Primary completion
2023-06
later than 1 of 10 live
Registered
37th of 61
by date
Lead sponsor
2 of 61
Korea University

Among the 61 studies in Liver Cirrhosis with a site in Korea, Republic of, this one is the 3rd largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 37th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

8 of the 61 studies in Liver Cirrhosis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Liver Cirrhosis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in patients with cirrhosis and compare the detection efficacy between tests.

Read the detailed description

Early diagnosis of HCC is the most important factor in improving the prognosis of the disease. A surveillance test for early diagnosis of HCC in Korea is to perform alfa fetoprotein (AFP) and abdominal sonography every 6-months in high-risk groups. However, the detection rate of HCC using AFP and abdominal sonography is very low. There are several reports that the combination of the multiple biomarker tests including AFP, AFP L3, and PIVKA-II increased the early HCC detection only one test. Therefore, in the surveillance test for HCC, the combination of three tests with sonography would be helpful in the early diagnosis of HCC. However, there was few prospective large-scale studies about this issue.

Compared with abdominal sonography, contrast-enhanced CT or MRI is more useful in finding intrahepatic lesions of liver cirrhosis. However, there is no evidence data on combining sono/CT and biomarkers could improve the diagnosis for early HCC. Thus, it is essential to verify this prospectively in the real clinical practices to make recommendations based on a high level of evidence in the future. The investigators are conducting a prospective study which examines three biomarker tests and sonography every six months and contrast-enhanced CT annually for HCC surveillance in patients with cirrhosis.

03

Conditions studied

  • Liver Cirrhosis
  • Hepatocellular Carcinoma
  • Surveillance

Keywords

  • Liver Cirrhosis
  • Hepatocellular Carcinoma
  • Surveillance
  • AFP-L3
  • AFP
  • PIVKA-II
  • Sonography
  • CT
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with liver cirrhosis meeting one of the followings:

    i. confirmed liver cirrhosis ii. Imaging findings with liver cirrhosis (liver surface undulation, irregularity, or nodularity by US, CT, or MRI) plus one of followings: liver stiffness measurement ≥ 12.5 kilopascal, esophago-gastric varices, thrombocytopenia (\<120,000/mm3), hypoalbuminemia (\<3.5 g/dL), splenomegaly ≥12 cm) iii. Imaging findings with liver cirrhosis together with biomarkers suggesting liver cirrhosis (APRI ≥2.0 or fibrosis-4 ≥3.6) iv. Imaging findings with liver cirrhosis with history of hepatic decompensation (ascites, esophago-gastric variceal bleeding, jaundice, hepatic encephalopathy))

  • Expected survival more than 1 year
  • score 5-10 at the time of enrollment
  • Serum creatinine ≤1.5mg/dL
  • Age between 19 and 75 years old
  • No significant underlying medical illness affecting patient's survival
  • Patients available for regular follow-up according to the study protocol

Exclusion criteria

Exclusion Criteria:

  • History of HCC
  • AFP >20 ng/mL
  • Hepatic nodule ≥ 1 cm by US or CT Exceptionally, nodules showing characteristic features of benign lesion such as hemangioma or pathologically conformed benign lesion are permitted for study inclusion.
  • Hepatic nodule less than 1 cm on US but imaging findings suggesting HCC by contrast enhanced US, CT, or MRI
  • score ≥ 11
  • History of liver transplantation
  • Expecting liver transplantation within 1 year
  • on CT contrast dye
  • Any for CT
  • Not able to perform abdominal US
  • Other uncontrolled
  • Patients taking warfarin
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,418 participants (estimated)

Study arms

  • Other
    Surveillance

    All participants will be examined with three biomarker tests and sonography every six months and contrast-enhanced CT annually.

    Diagnostic Test: AFP-L3 · Diagnostic Test: AFP · Diagnostic Test: PIVKA-II · Diagnostic Test: Sonography · Diagnostic Test: CT

Interventions

  • Diagnostic testAFP-L3

    AFP-L3 will be tested using serum sample every 6 months.

    Also known as: Lens culinaris agglutinin-reactive fraction of AFP

  • Diagnostic testAFP

    AFP will be tested using serum sample every 6 months.

    Also known as: Alpha fetoprotein

  • Diagnostic testPIVKA-II

    PIVKA-II will be tested using serum sample every 6 months.

    Also known as: Protein induced by vitamin K absence or antagonist-II, des-gamma-carboxy prothrombin

  • Diagnostic testSonography

    Sonography will be tested by experts every 6 months.

    Also known as: Ultrasound, US

  • Diagnostic testCT

    Contrast-enhanced CT will be tested annually.

    Also known as: Computed tomography

06

What researchers measure

Primary outcomes

  1. HCC occurrence

    Detection of HCC occurrence by three biomarkers and two image modalities

    Time frame: 3 years after enrollment

Secondary outcomes

  1. Early HCC occurrence

    Detection of HCC less than 2cm

    Time frame: 3 years after enrollment

07

Study locations

15 of 15 sites recruiting
08

References and documents

Publications

  • El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011 Sep 22;365(12):1118-27. doi: 10.1056/NEJMra1001683. No abstract available. PubMed 21992124 ↗
  • Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460. PubMed 25918260 ↗
  • Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol. 2015 Apr 7;21(13):3826-42. doi: 10.3748/wjg.v21.i13.3826. PubMed 25852267 ↗
  • European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001. No abstract available. Erratum In: J Hepatol. 2012 Jun;56(6):1430. PubMed 22424438 ↗
  • Yim SY, Seo YS, Jung CH, Kim TH, Lee JM, Kim ES, Keum B, Jong YK, An H, Kim JH, Yim HJ, Kim DS, Jeen YT, Yeon JE, Lee HS, Chun HJ, Byun KS, Um SH, Kim CD, Ryu HS. The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years? Liver Int. 2016 Mar;36(3):445-53. doi: 10.1111/liv.12960. Epub 2015 Oct 12. PubMed 26352789 ↗
  • Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009 Jan;7(1):104-13. doi: 10.1016/j.cgh.2008.08.041. Epub 2008 Sep 17. PubMed 18849011 ↗
  • Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, Kosaka K. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 1990 Aug;99(2):508-18. doi: 10.1016/0016-5085(90)91034-4. PubMed 1694805 ↗
  • Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, Satomura S, Matsuura S, Kawai T, Hirai H. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993 Nov 15;53(22):5419-23. PubMed 7693340 ↗
  • Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, Seki T, Kudo M, Tanaka M; Collaborative Hepato-Oncology Study Group of Japan. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol. 2001 Dec;16(12):1378-83. doi: 10.1046/j.1440-1746.2001.02643.x. PubMed 11851836 ↗
  • Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006 Sep;101(9):2038-43. doi: 10.1111/j.1572-0241.2006.00681.x. Epub 2006 Jul 18. PubMed 16848811 ↗
  • Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339. PubMed 23372355 ↗
  • Yoon YJ, Han KH, Kim DY. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol. 2009;44(7):861-6. doi: 10.1080/00365520902903034. PubMed 19391065 ↗
  • Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015 Apr 7;21(13):3928-35. doi: 10.3748/wjg.v21.i13.3928. PubMed 25852278 ↗
  • Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016 Mar;51(3):344-53. doi: 10.3109/00365521.2015.1082190. Epub 2015 Sep 4. PubMed 26340708 ↗
  • Di Martino M, De Filippis G, De Santis A, Geiger D, Del Monte M, Lombardo CV, Rossi M, Corradini SG, Mennini G, Catalano C. Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol. 2013 Apr;23(4):887-96. doi: 10.1007/s00330-012-2691-z. Epub 2012 Nov 18. PubMed 23179521 ↗
  • Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014 Oct;3(3-4):458-68. doi: 10.1159/000343875. PubMed 26280007 ↗
  • Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, Zakher B, Pappas M, Graham E, Sullivan SD. Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 May 19;162(10):697-711. doi: 10.7326/M14-2509. Erratum In: Ann Intern Med. 2015 Jun 16;162(12):880. PubMed 25984845 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2016 (actual). Primary completion is estimated for Jun 2023, 83 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 83 months is above that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2020
First posted
Jun 4, 2020
StartActual
Jul 1, 2016
Primary completionEst.
Jun 30, 2023
CompletionEst.
Feb 28, 2026
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04414956
Lead sponsor
Korea University
Collaborators
Korea University Ansan Hospital, Soonchunhyang University Hospital, Korea University Guro Hospital, The Catholic University of Korea, Samsung Medical Center, Asan Medical Center, Korea University Anam Hospital, Keimyung University Dongsan Medical Center, Severance Hospital, Hanyang University, Konkuk University Hospital, Seoul National University Hospital, Inje University, Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Responsible party
Soon Ho Um (Professor, Korea University) — Principal investigator
First posted
Jun 4, 2020
Start date
Jul 1, 2016
Primary completion
Jun 30, 2023 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Jun 4, 2020

Study contacts

Hyung Joon Yim, MD,PhD
Contact
gudwns21@korea.ac.kr
+82-31-412-6565
Soon Ho Um, MD,PhD
Contact
umsh@korea.ac.kr
+82-2-920-5019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion